Evidence map›Paper›PMID 41968325›Full record

ArticleMicrobial cell factories2026

Effect of the biomass production conditions on survival of the probiotic yeast Saccharomyces cerevisiae var. boulardii in a laboratory model of the gastrointestinal tract.

Dorota A Rzechonek, Lisbeth Olsson

Abstract read
In one paragraph

Article in Microbial cell factories, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Dorota A RzechonekDepartment of Life Sciences, Division of Industrial Biotechnology, Chalmers University of Technology, Chalmersplatsen 4, 412 96, Gothenburg, Sweden.
Lisbeth OlssonDepartment of Life Sciences, Division of Industrial Biotechnology, Chalmers University of Technology, Chalmersplatsen 4, 412 96, Gothenburg, Sweden. lisbeth.olsson@chalmers.se.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSaccharomyces cerevisiae var. boulardii is a commercialized probiotic yeast used for the treatment of diarrhea and other disorders of the gastrointestinal tract. While the impact of this yeast on the body and its interaction with other microorganisms is well studied, little information about the production of probiotic yeasts is publicly available. This study aimed to improve the performance of S. boulardii by optimizing yeast biomass production.

resultsWe developed a simple in vitro model that mimicked the conditions of the gastrointestinal tract. The model allowed us to detect differences in performance between yeast produced under different conditions. The three-step set-up consisted of incubations in stomach-like and small intestine-like juice, followed by cultivation under colon-simulating conditions with intestine-like media (ILM) at varying pH. S. boulardii strains were initially unable to growth in ILM at pH 7.0. However, by optimizing production conditions, we obtained yeast capable of surviving the whole pH range in ILM. Yeast biomass displaying the best performance was harvested in early stationary phase from cultures grown at 37 °C in YPD medium. Moreover, during cultivation under colon-like conditions, we detected acetic acid, which is a desirable feature of probiotic microorganisms.

conclusionThe choice of production conditions is crucial for the quality and functionality of probiotic yeast biomass. Differences in biomass viability can be observed by applying a model of the gastrointestinal system, which can be a useful tool in further studies on probiotic yeasts.

Indexed as

BiomassGastrointestinal TractProbioticsSaccharomyces boulardiiSaccharomyces cerevisiaeCulture MediaFermentationHydrogen-Ion ConcentrationMicrobial ViabilityCulture MediaAcetic acidBiomass productionProbioticsSaccharomyces boulardii

Identifiers

PMID41968325
PMCPMC13088855

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.